Where is Pulmocide headquartered?

Pulmocide is located in London, england.

Who invested in Pulmocide?

Pulmocide has 13 investors including Geekdom Fund And Geekdom Fund.

When was the last funding round for Pulmocide?

Pulmocide closed its lastf unding roundon Jul 19, 2017 from a Convertible Note round.

Company Information
Company Timeline (Coming Soon)

pulmocide.com

Pulmocide

Pulmocide is an England-based biopharmaceutical company that researches and develops novel inhaled therapies for the treatment of chronic respiratory diseases.

Business Model:

Revenue: $5M

Employees: 11-50

Geographic Data

Address: 44 Southampton Buildings

City: London

State: england

Zip: WC2A 1AP

Country: GB

Financial Info

Stage:

grant

Raised Last:

$4M

Raised Total:

$153M

Social

Twitter

Crunchbase

Metrics

4,561,639Website Global Rank

2,050Website Monthly Traffic

Twitter Followers

Description

Pulmocide is an England-based biopharmaceutical company that researches and develops novel inhaled therapies for the treatment of chronic respiratory diseases.

Contact Phone:

Contact Email:

Investments

Announced Date	Company	Transaction	Money Raised

Funding Rounds

Announced Date	Transaction	Number of Investors	Money Raised	Lead Investors
5/2021	Series C		$0	Adjuvant Capital Asahi Kasei Pharma F-Prime Capital IP Group Jeito Capital Johnson &a; Johnson Innovation – JJDC Longwood Fund SR One SV Health Investors Adjuvant Capital Asahi Kasei Pharma F-Prime Capital IP Group Jeito Capital Johnson &a; Johnson Innovation – JJDC Longwood Fund SR One SV Health Investors
11/2013	Series A		$27.5M	Imperial Innovations Group plc S.V. Life Sciences Fidelity Biosciences Johnson & Johnson Development Corporation
11/2013	Series A	4	$27.6M	F-Prime Capital Imperial Innovations Johnson &a; Johnson Development Corporation SV Health Investors F-Prime Capital Imperial Innovations Johnson &a; Johnson Development Corporation SV Health Investors
12/2021	Grant	1	$3.5M	Cystic Fibrosis Foundation Cystic Fibrosis Foundation
12/2022	Series C		$52M	Pictet Alternative Advisors Vivo Capital SV Health Investors Jeito Capital SR One IP Group plc F-Prime Capital Johnson & Johnson Innovation Adjuvant Capital Asahi Kasei Pharma Longwood Fund the Cystic Fibrosis Foundation
3/2017	Series B	6	$30.4M	F-Prime Capital Johnson &a; Johnson Innovation – JJDC Longwood Fund SR One SV Health Investors Touchstone Innovations F-Prime Capital Johnson &a; Johnson Innovation – JJDC Longwood Fund SR One SV Health Investors Touchstone Innovations
12/2022	Series C		$0	Vivo Capital SV Health Investors SR One Pictet Alternative Advisors Longwood Fund Johnson &a; Johnson Innovation – JJDC Jeito Capital IP Group F-Prime Capital Cystic Fibrosis Foundation Adjuvant Capital Asahi Kasei Pharma Adjuvant Capital Asahi Kasei Pharma Vivo Capital SV Health Investors SR One Pictet Alternative Advisors Longwood Fund Johnson &a; Johnson Innovation – JJDC Jeito Capital IP Group F-Prime Capital Cystic Fibrosis Foundation Adjuvant Capital Asahi Kasei Pharma Adjuvant Capital Asahi Kasei Pharma
5/2021	Series C	9	$92M	Jeito Capital Adjuvant Capital Asahi Kasei Pharma SV Health Investors SR One IP2IPO F-Prime Capital Johnson & Johnson Innovation Adjuvant Capital Asahi Kasei Pharma F-Prime Capital IP Group Jeito Capital Johnson &a; Johnson Innovation – JJDC Longwood Fund SR One SV Health Investors

Acquisitions

Announced Date	Name	Price

Employee Demographics

Employee Departments

Employee States

Similar Companies

Uniview Singapore VEID	Revenue: 0 - 100000 Employees: Industry: Software	Details
Konkuk University Medical Center	Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education	Details
Daemon Technologies	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain	Details
Ace International Trade	Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial	Details
An Hòa Communications	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising	Details